Shield Therapeutics

United Kingdom
Weybridge, England, United Kingdom, KT13 0TT

Company profile

Shield Therapeutics company profile

Shield Therapeutics is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. During 2011 Shield will be commencing global pivotal Phase III studies of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and subsequently chronic kidney disease. The Company is headquartered in Wollerau, Switzerland.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2008-01-01, Year

Headquarters

Postal code
KT13 0TT
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$19.9M
Last funding
Post IPO Equity / $2M / 2025-09-15
Last equity funding
Post IPO Equity / $2M
Investors
5
Lead investors
2
Founders
2
Articles
78
Exited on
2016-02-26

Founders and investors

Founders

Carl SterrittChristian Schweiger

Lead investors

Inventages Venture Capital Investment Inc.SWK Holdings

Investors

AOP Global HealthCavendish Corporate FinanceInventages Venture Capital Investment Inc.Peel HuntSWK Holdings